Kantarjian et al53 assessed the efficacy and protection of dasatinib, as compared with imatinib, for the first-line treatment of CML-CP. 5 hundred and nineteen individuals with freshly diagnosed CML-CP had been randomly assigned to acquire dasatinib in a dose of a hundred mg after every day (259 clients) or imatinib at a dose of 400 mg once each da

The internet site is protected. The https:// makes certain that you are connecting to the Formal Web page and that any info you supply is encrypted and transmitted securely.The site is secure. The https:// makes sure that you'll be connecting to your official Web site Which any facts you present is encrypted and transmitted securely.See favourites